Revenue (Quarterly) Chart

View Revenue (Quarterly) for SWDCF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Revenue (Quarterly) Chart
Start Trial

Historical Revenue (Quarterly) Data

View and export this data back to 2015. Start Trial.
Date Value
June 30, 2026 71.55M
March 31, 2026 71.14M
December 31, 2025 72.53M
September 30, 2025 74.90M
June 30, 2025 66.90M
March 31, 2025 60.06M
December 31, 2024 61.34M
September 30, 2024 61.50M
June 30, 2024 58.98M
March 31, 2024 57.47M
December 31, 2023 58.79M
September 30, 2023 55.68M
June 30, 2023 54.27M
March 31, 2023 50.12M
December 31, 2022 46.37M
September 30, 2022 45.85M
June 30, 2022 47.90M
March 31, 2022 40.43M
December 31, 2021 28.80M
September 30, 2021 25.57M
June 30, 2021 19.02M
March 31, 2021 15.94M
December 31, 2020 11.69M
Date Value
September 30, 2020 7.845M
June 30, 2020 3.308M
March 31, 2020 3.897M
December 31, 2019 3.544M
September 30, 2019 3.312M
June 30, 2019 3.215M
March 31, 2019 3.330M
December 31, 2018 3.071M
September 30, 2018 2.683M
June 30, 2018 2.957M
March 31, 2018 2.673M
December 31, 2017 2.722M
September 30, 2017 2.650M
June 30, 2017 2.085M
March 31, 2017 2.568M
December 31, 2016 1.701M
September 30, 2016 1.577M
June 30, 2016 1.358M
March 31, 2016 1.625M
December 31, 2015 0.5921M
September 30, 2015 0.8617M
June 30, 2015 0.9786M
March 31, 2015 0.7497M

Revenues Definition

Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.

Read full definition.

Revenue (Quarterly) Range, Past 5 Years

View Revenue (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue (Quarterly) Benchmarks

View Revenue (Quarterly) Benchmarks
Start Trial
Orexo AB 0.3738M
Camurus AB 74.97M
Moberg Pharma AB 0.6157M
Infant Bacterial Therapeutics AB 0.00
AstraZeneca PLC 15.26B